Literature DB >> 22970008

Survivin expression in human lung cancer and the influence of its downregulation on the biological behavior of human lung cancer cells.

Xiang-Qi Chen1, Sheng Yang, Ming-Qiang Kang, Zhi-Ying Li, Hui-Shan Lu, Ting-Yan Lin.   

Abstract

The aim of the present study was to detect the expression of survivin in human lung cancer and to investigate the influence of its downregulation on the biological behavior of A549 lung cancer cells. The high expression of survivin in human lung cancer was verified by immunohistochemistry. Survivin small interfering RNA (siRNA) and unrelated sequence were synthesized and the siRNA lentiviral vector was constructed. The vector was transfected into A549 lung cancer cells, in which the clone with stable expression was screened out. We blocked the expression of survivin mRNA and protein by RNA interference (RNAi) technique. The downregulation of survivin mRNA and protein expression was confirmed by real-time quantitative PCR and western blotting. The proliferative activity and growth rate of A549 cells were determined by colony formation assay and mononuclear cell direct cytotoxicity assay (MTT assay). The reconstituted basement membrane (RBM) penetrating capacity was determined by cell invasion assay. The cell movement and migratory capacity were detected by wound-healing repair assay. The results showed that the sequence-specific siRNA significantly downregulated the expression of survivin at both the mRNA and protein levels. Downregulation of survivin expression dramatically decreased the invasive and metastatic capacities of the cells, suppressed the proliferation, decelerated the rate of growth, reduced the number of clones on soft agar and decreased the capacity of RBM penetration and migration. In conclusion, survivin, which plays an important role in carcinogenesis and development of lung cancer, can be effectively downregulated using the RNAi technique.

Entities:  

Year:  2012        PMID: 22970008      PMCID: PMC3438707          DOI: 10.3892/etm.2012.525

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  19 in total

Review 1.  Promises and challenges in developing RNAi as a research tool and therapy.

Authors:  Mouldy Sioud
Journal:  Methods Mol Biol       Date:  2011

2.  Compartmentalized phosphorylation of IAP by protein kinase A regulates cytoprotection.

Authors:  Takehiko Dohi; Fang Xia; Dario C Altieri
Journal:  Mol Cell       Date:  2007-07-06       Impact factor: 17.970

3.  Expression of inhibitors of apoptosis (IAP) proteins in non-small cell human lung cancer.

Authors:  Hans-Stefan Hofmann; Andreas Simm; Andreas Hammer; Rolf-Edgar Silber; Babett Bartling
Journal:  J Cancer Res Clin Oncol       Date:  2002-09-05       Impact factor: 4.553

Review 4.  Targeting survivin in cancer: patent review.

Authors:  Jagat R Kanwar; Sishir K Kamalapuram; Rupinder K Kanwar
Journal:  Expert Opin Ther Pat       Date:  2010-12       Impact factor: 6.674

Review 5.  [RNA interference for cancer therapies].

Authors:  Eishi Ashihara
Journal:  Gan To Kagaku Ryoho       Date:  2010-11

Review 6.  Survivin, cancer networks and pathway-directed drug discovery.

Authors:  Dario C Altieri
Journal:  Nat Rev Cancer       Date:  2008-01       Impact factor: 60.716

7.  Chemically synthesized human survivin does not inhibit caspase-3.

Authors:  Changqing Li; Zhibin Wu; Min Liu; Marzena Pazgier; Wuyuan Lu
Journal:  Protein Sci       Date:  2008-06-06       Impact factor: 6.725

Review 8.  Who is at high risk for lung cancer? Population-level and individual-level perspectives.

Authors:  Anthony J Alberg; Jill Nonemaker
Journal:  Semin Respir Crit Care Med       Date:  2008-06       Impact factor: 3.119

Review 9.  New wirings in the survivin networks.

Authors:  D C Altieri
Journal:  Oncogene       Date:  2008-10-20       Impact factor: 9.867

10.  DNA methylation inhibits p53-mediated survivin repression.

Authors:  N H Nabilsi; R R Broaddus; D S Loose
Journal:  Oncogene       Date:  2009-04-13       Impact factor: 9.867

View more
  7 in total

1.  Association between survivin genetic polymorphisms and epidermal growth factor receptor mutation in non-small-cell lung cancer.

Authors:  Tu-Chen Liu; Ming-Ju Hsieh; Wen-Jun Wu; Ying-Erh Chou; Whei-Ling Chiang; Shun-Fa Yang; Shih-Chi Su; Thomas Chang-Yao Tsao
Journal:  Int J Med Sci       Date:  2016-11-23       Impact factor: 3.738

2.  Evaluation of antitumor activity of survivin short interfering RNA delivered by lipid nanoparticles in colon cancer in vitro and in vivo.

Authors:  Tianyou Wang; Ziqin Liu; Zhaoxia Zhang; Suoqin Tang; Mei Yue; Shunqiao Feng; Mengze Hu; Litian Xuan; Yanfei Chen
Journal:  Oncol Lett       Date:  2017-06-16       Impact factor: 2.967

3.  Anticancer Activity of Tetrandrine by Inducing Apoptosis in Human Breast Cancer Cell Line MDA-MB-231 In Vivo.

Authors:  Chun-Hui Wang; Jia-Min Yang; Yu-Bo Guo; Jing Shen; Xiao-Hua Pei
Journal:  Evid Based Complement Alternat Med       Date:  2020-06-30       Impact factor: 2.629

4.  Myricanol 5-fluorobenzyloxy ether regulation of survivin pathway inhibits human lung adenocarcinoma A549 cells growth in vitro.

Authors:  Guan-Hai Dai; Xuan Chen; Ze-Ming Ren; Chen-Jie Dai; Ye-Ling Tong; Ke-Qun Chai
Journal:  BMC Complement Med Ther       Date:  2020-09-03

5.  Discovery of Survivin Inhibitors Part 1: Screening the Harbor Branch Pure Compound Library.

Authors:  Esther A Guzmán; Tara P Pitts; Kirstie R Tandberg; Priscilla L Winder; Amy E Wright
Journal:  Mar Drugs       Date:  2021-01-30       Impact factor: 5.118

6.  Identifying General Tumor and Specific Lung Cancer Biomarkers by Transcriptomic Analysis.

Authors:  Beatriz Andrea Otálora-Otálora; Daniel Alejandro Osuna-Garzón; Michael Steven Carvajal-Parra; Alejandra Cañas; Martín Montecino; Liliana López-Kleine; Adriana Rojas
Journal:  Biology (Basel)       Date:  2022-07-20

7.  MACC1 induces metastasis in ovarian carcinoma by upregulating hepatocyte growth factor receptor c-MET.

Authors:  Xiu-Jie Sheng; Zhen Li; Man Sun; Zhi-Hui Wang; Dong-Mei Zhou; Jian-Qi Li; Qin Zhao; Xiao-Fang Sun; Qi-Cai Liu
Journal:  Oncol Lett       Date:  2014-05-27       Impact factor: 2.967

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.